L'intérêt à découvert pour Pfizer donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Pfizer. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Pfizer (NYSE:PFE) Stock, Rapport sur les intérêts à découvert

PFIZER INC

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

Dr. Vinay Prasad, the U.S. Food and Drug Administration&#8217;s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">them for broader use</a>.
The decision reflects a growing pattern of vaccine restrictions under the leadership of the U.S. Health and Human Services Secretary Robert F. Kennedy Jr.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for individuals aged 12 and older, citing favorable risk-benefit analyses.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-" rel="noreferrer noopener">Novavax&#8217;s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial</a>
However, citing federal documents released Wednesday, ABC News reported <a target="_blank" href="https://abcnews.go.com/Health/wireStory/fda-vaccine-official-restricted-covid-vaccine-approvals-advice-123431749" rel="noreferrer noopener">that</a> Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.
In a five-page memo, Prasad wrote that &#8220;even rare vaccination-related harms, both known and unknown, now have a higher chance of outweighing potential benefits,&#8221; highlighting the need for more cautious vaccine policy.
The vaccines were eventually approved in May, but under the narrower eligibility <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45537919/fda-limits-annual-covid-19-boosters-to-high-risk-americans-demands-new-trials-for-healthy-adults-in-policy-shift-under-rfk-jr" rel="noreferrer noopener">criteria dictated by Prasad</a>.
Novavax&#8217;s shot, Nuvaxovid, is the only protein-based COVID vaccine available in the U.S., while Moderna&#8217;s mNexspike is a lower-dose, updated version of its <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">original mRNA-based vaccine</a>.
Prasad also cited the risk of myocarditis, a rare heart inflammation, especially in younger people, as a key reason for restricting Moderna&#8217;s shot.
He directed the company to conduct further studies as a condition for approval. The FDA also added updated warning labels for Moderna and Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) vaccines regarding myocarditis, though external researchers say such cases are typically mild and resolve quickly.
Top FDA leaders rarely intervene in the product review, making Prasad&#8217;s decision notable. He was appointed in May after Dr. Peter Marks resigned over policy disagreements with Kennedy.
In May, Kennedy, in a&nbsp;video&nbsp;posted to the social media platform X, announced that the COVID-19 vaccine will no longer be among the recommended vaccines for pregnant women and healthy children on the U.S. Centers for Disease Control and <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Prevention&#8217;s immunization schedule</a>.
Price Action: At the last check on Thursday, Moderna (MRNA) stock saw an increase of 1.34%, trading at $30.69, while Novavax (NVAX) stock rose by 0.67% to $6.81. Pfizer (PFE) stock was also up at the last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" target="_blank" rel="noreferrer noopener">AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment</a></li>
</ul>
Photo via Shutterstock

Biotech

Government

Large Cap

News

Health Care

General

MRNA

NVAX

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval

On July 2, 2025, it was reported that Senator Ron L Wyden executed a sale of Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) stock, valued between $1,001 and $15,000. The transaction, recorded in the July filing, was made on June 3, 2025.
At the time of writing, Pfizer shares are trading up 0.33% at $25.4.
<h3>Senator's Recent Trading Activity</h3>
In the past three years, Ron L Wyden made 20 stock trades totaling more than $596 thousand. The largest trades involved stocks like PayPal Holdings and United Parcel Service. Their most notable trades made recently include key transactions: 
<ul>
<li>Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Ron L Wyden's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>PFE</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-06-03</td>
</tr>
</tbody>
</table>
If you want to stay updated on Ron L Wyden's trades and other congressional members, check out our <a href="https://www.benzinga.com/gov-trades/members/ron-l-wyden">government trades tool</a> to track their activity in real time!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Politics

Trading Ideas

Recent Report Shows That Sen. Ron L Wyden Sold Up to $15K Worth of Pfizer Stock

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.79%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI&#x2122; in Hemophilia A or B with inhibitors.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="917" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png" alt="" class="wp-image-971905" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-768x688.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.99%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 67%.</li>
<li>RBC Capital analyst Ben Hendrix maintained an Outperform rating and boosted the price target from $74 to $81 on May 5, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31 to discuss second quarter 2025 financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">CVS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png" alt="" class="wp-image-971907" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.93%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On July 2, the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck's new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for Winrevair (sotatercept-csrk).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="911" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png" alt="" class="wp-image-971910" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-768x697.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

<a href="https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html" title="https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html">https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html</a>

BNTX

'Top F.D.A. Official Overrode Scientists on Covid Shots; Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.' - NY Times

The House Judiciary Committee has subpoenaed Dr. Philip Dormitzer, a former Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) executive, in connection with an investigation into claims that the company intentionally delayed the release of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">clinical testing results</a> for its COVID-19 vaccine until after the 2020 presidential election.
The move signals an escalation in the panel's probe into whether political considerations influenced Pfizer's vaccine announcement timeline.
Dormitzer, who later joined British drugmaker GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), is considered a key witness in the inquiry.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46123159/pfizer-seeks-label-expansion-for-hemophilia-drug-after-promising-data" rel="noreferrer noopener">Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data</a>
Benzinga reached out to Pfizer for comment.
According to the committee, he has not voluntarily complied with previous requests to appear or provide documents.
The subpoena, first reported by CNN, reflects lawmakers&#8217; belief that Dormitzer&#8217;s testimony is central to understanding internal decision-making at Pfizer during the development of the vaccine.
The committee points to allegations that Dormitzer, after joining GSK, told colleagues that Pfizer had deliberately delayed disclosing the vaccine&#8217;s effectiveness until after Election Day.
The CNN <a target="_blank" href="https://edition.cnn.com/2025/06/30/politics/pfizer-covid-vaccine-philip-dormitzer" rel="noreferrer noopener">report </a>added that the Wall Street Journal previously reported that GSK had flagged those statements to federal prosecutors in New York.
According to House Judiciary Chair Jim Jordan, GSK provided information from a human resources meeting in November 2024 in which Dormitzer allegedly expressed concern about being investigated by a future Trump administration, suggesting the vaccine announcement timing was "not a coincidence."
Further, Jordan's letter cites claims that Dormitzer informed colleagues that Pfizer&#8217;s top R&amp;D leadership intentionally slowed clinical testing so that it would not conclude before the election results were known. The Judiciary Committee has received some records from GSK but has not made them public.
Pfizer announced the COVID-19 vaccine's effectiveness on Nov. 9, 2020, six days after Election Day.
CEO Albert Bourla has previously denied political motives, telling CNN that the timing was based solely on data readiness and regulatory review, not election considerations.
While the committee has not issued a subpoena to Pfizer, it seeks information directly from the company as the investigation progresses.
Price Action: PFE stock is currently 0.80% higher at $25.24, as of the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46226585/microsoft-cuts-9000-jobs-in-second-2025-layoff" target="_blank" rel="noreferrer noopener">Microsoft Cuts 9,000 Jobs In Second 2025 Layoff As AI Expansion Pushes Cost Controls</a></li>
</ul>
Photo: Shutterstock

Legal

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons

<a href="https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true</a>

'RFK Jr. Vows Overhaul of Lawsuit-Sparing Vaccine Injury Program'- Bloomberg

Personal finance expert Suze Orman says she&#8217;s confident the stock market is headed higher, despite some alarming signs in the broader economy. In her recent <a href="https://www.youtube.com/watch?v=eoC3d8kt6e4">video</a>, she acknowledged that things feel unstable right now, but urged her audience to stay calm and take a long-term view.
<h2 class="wp-block-heading">Unusual Economic Signals</h2>
&#8220;There is something going on in this economy that I really don&#8217;t like,&#8221; Orman said, citing how traditional patterns are breaking. Typically, when markets drop, investors move into bonds, causing bond prices to rise and interest rates to fall. But that hasn&#8217;t been happening. &#8220;Interest rates in <a href="https://www.benzinga.com/25/05/45654448/bond-market-caught-between-rate-cut-hopes-and-fed-cautionwhat-investors-can-do-now">bonds</a> went up and up and up,&#8221; she said. &#8220;That isn&#8217;t what you want to see in normal markets.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Another red flag: the U.S. dollar. Orman explained that during times of global uncertainty, foreign money usually flows into the dollar, strengthening it. But instead, &#8220;<a href="https://www.benzinga.com/markets/economic-data/25/06/45974992/everyone-now-hates-the-dollar-is-that-the-ultimate-buy-signal">the dollar has been getting weaker</a> and weaker and weaker.&#8221;
She suggested this could mean foreign investors are losing confidence in the U.S. &#8220;Maybe it&#8217;s that foreign countries don&#8217;t quite have the faith in us anymore that they used to. We haven&#8217;t exactly <a href="https://www.benzinga.com/25/03/44131125/tariff-update">been nice to them</a>.&#8221;
<h2 class="wp-block-heading">Shifting Her Own Strategy</h2>
With her own treasuries maturing, Orman said she is now choosing dividend-paying stocks instead of rolling her money back into treasuries. &#8220;Many <a href="https://www.benzinga.com/money/best-dividend-paying-stocks">dividend-paying stocks</a> right now are paying more in a dividend than the Treasury is paying in interest rates,&#8221; she said.
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
She emphasized the importance of dollar-cost averaging: investing smaller amounts over time. This way, if stock prices fall, investors can buy more shares. &#8220;Even if it goes down because the markets go down&#8230; [your] income is fixed in the dividend, [so] your interest rate also goes up in there,&#8221; she explained.
One example she gave was Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), which has been trading around $24 a share with a <a href="https://www.benzinga.com/content/45601072/pfizers-7-5-dividend-income-haven-or-house-of-cards">dividend yield of about 7%</a>. &#8220;Now, is it possible that maybe they could cut the dividend? They&#8217;re not going to get rid of the dividend, as far as I&#8217;m concerned.&#8221;
<h2 class="wp-block-heading">Staying Invested In The Future</h2>
Orman advised investors to focus on sectors that reflect the future, particularly artificial intelligence and technology. She specifically recommended ETFs like VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). &#8220;I want you to be investing in the future, not in the past anymore,&#8221; she said. &#8220;Artificial intelligence has absolutely changed the face of money and the face of the future.&#8221;
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
Despite today's economic uncertainty, Orman remains optimistic. &#8220;Believe it or not, I have total belief that these markets are going to continue up without a shadow of a doubt,&#8221; she said. Even if she turns out to be only half right, she advised investors to act accordingly: invest 50% now and the rest later if prices fall.
&#8220;I&#8217;m still a total believer in the stock market. I think it is very, very possible you could see the [<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45932660/exclusive-sp-500-new-all-time-highs-again-2025">S&amp;P 500</a>] skyrocket. I am a total believer in dividend-paying stocks,&#8221; she said. And if you don't need the income now, she added, &#8220;it is essential that you are reinvesting those dividends.&#8221;
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Suze Orman Believes The Stock Market Will Continue Climbing 'Without A Shadow Of A Doubt'

Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) released topline results from the Phase 3 BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.
Phase 3 BASIS study in patients without inhibitors supported the FDA approval of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">Hympavzi in October 2024</a>.
The study met the primary endpoint and key secondary bleeding endpoints, demonstrating the superiority of once-weekly subcutaneous Hympavzi in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46111475/pfizer-announces-positive-topline-phase-3-results-for-hympavzi-in-hemophilia-a-or-b-with-inhibitor" rel="noreferrer noopener">approaches are needed</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44560065/fda-approves-sanofis-hemophilia-drug" rel="noreferrer noopener">FDA Approves Sanofi&#8217;s Hemophilia Drug</a>
The BASIS trial demonstrated that prophylactic treatment with Hympavzi resulted in a statistically significant and clinically relevant reduction in annualized bleeding rate (ABR) of treated bleeds in people with severe hemophilia A or B with inhibitors.
Forty-eight people living with hemophilia were treated with Hympavzi during 12 months versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in the six-month lead-in period.
Hympavzi was superior to on-demand treatment with a 93% reduction in ABR over 12 months (ABR 1.39 vs ABR on-demand 19.78; p &lt; 0.0001).
The superiority of Hympavzi was also demonstrated across all bleeding-related secondary endpoints, spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds, Pfizer announced on Thursday.
Hympavzi was generally well-tolerated, consistent with the non-inhibitor cohort of the BASIS study and Phase 1/2 results. No deaths or thromboembolic events were reported.
Analyses of the full Phase 3 dataset from the inhibitor cohort of the BASIS study are ongoing, and additional data will be presented at upcoming medical meetings.
Hympavzi&#8217;s mechanism of action is differentiated from those of FVIII and FIX replacement treatments. Instead of replacing missing or insufficient clotting factors, Hympavzi is intentionally designed to target tissue factor pathway inhibitor (TFPI), one of the body&#8217;s natural mechanisms that inhibits the initiation of blood clotting.
By targeting the Kunitz 2 domain of TFPI, Hympavzi may help re-establish balance between bleeding and blood clot formation. Its goal is to offer a combination of bleed protection, good tolerability, and straightforward administration.
Pfizer plans to discuss these data with regulatory authorities to initiate regulatory filings for Hympavzi for hemophilia patients with inhibitors.
Price Action: PFE stock is trading lower by 0.05% to $24.25 at last check Thursday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46109624/rfk-jr-overhauls-cdc-vaccine-panel-sparking-expert-backlash-boycott-from-top-medical-group" target="_blank" rel="noreferrer noopener">RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group</a></li>
</ul>
Photo by ShU studio via Shutterstock

Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data

<a href="https://www.youtube.com/watch?v=z-16fImZoEc">https://www.youtube.com/watch?v=z-16fImZoEc</a>
&nbsp;

U.S. CDC Advisory Panel Votes 5-1 In Favor Of Children 18 Years & Younger Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of Pregnant Women Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of All Adults Receiving Seasonal Flu Shot Only In Single Dose Forms That Are Free From Thimerosal

U.S. CDC Vaccine Advisory Panel Votes 7-0 In Favor Of Adding Preventive RSV Therapies To Vaccines For Children Resolution

<ul>
<li>Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to on-demand treatment in patients 12 years and older</li>
<li>HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection that required minimal preparation</li>
</ul>

Pfizer Announced Topline Results From The Phase 3 Basis Study Of Hympavzi (Marstacimab) For Adults And Adolescents With Hemophilia A Or B With Inhibitors, The Study Met The Primary Endpoint And Key Secondary Bleeding Endpoints Demonstrating Superiority Of Once-Weekly Subcutaneous Hympavzi In Improving Key Bleeding Outcomes Compared To On-demand Treatment

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.
What Happened: On Wednesday, the Advisory Committee on Immunization Practices reconvened under controversy, just weeks after Kennedy dismissed all 17 previous members of the committee and replaced them with his appointees, according to Reuters.
Criticism has since intensified after the panel&#8217;s agenda was abruptly changed only one day before the meeting, while adding a presentation on thimerosal, a vaccine preservative whose alleged risks have been repeatedly debunked by mainstream science. 
The presentation was delivered by Lyn Redwood, former leader of Children&#8217;s Health Defense, an anti-vaccine organization originally founded by Kennedy himself.
The reconstituted panel is already seeing a fallout, with Dr. Michael Ross, one of the newly appointed members, resigning unexpectedly before the first meeting was held. Two other Centers for Disease Control and Prevention staff members also left amid the chaos.
At least half of Kennedy&#8217;s appointees have publicly questioned vaccine safety in the past, leading organizations such as the American Academy of Pediatrics, a non-voting participant of these meetings, to skip, citing a lack of scientific credibility and procedural transparency. The organization plans to publish its evidence-based childhood vaccine schedules instead.
The panel&#8217;s chair, Dr. Martin Kulldorff, stated that the committee would review individual vaccines, as well as the cumulative effects and scheduling of childhood immunizations.
The committee also postponed a key vote on an RSV vaccine intended for children, further heightening uncertainty around upcoming vaccine recommendations.
Why It Matters: The overhaul of the CDC's vaccine schedules stands to have a significant impact on pharma companies, especially those with exposure to childhood vaccines. 
For instance, Pfizer Inc. and Moderna Inc., with their Respiratory Syncytial Virus (RSV) vaccines, stand to see some headwinds due to the committee postponing its vote on the vaccine.
Similarly, Merck &amp; Co. Inc., having reported $540 million in revenue during its <a href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million">first quarter results</a> from its <a href="https://www.benzinga.com/trading-ideas/long-ideas/19/04/13514693/nyc-mandates-measles-vaccinations-merck-is-the-exclusive-manufacturer">measles-mumps-rubella (MMR) vaccine</a> series, could see a material impact as a result of the vaccine advisory committee&#8217;s stance.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>Potential Impact</th>
<th class="has-text-align-center" data-align="center">YTD Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Outsized exposure to childhood vaccination schedules, with its MMR series.</td>
<td class="has-text-align-center" data-align="center">-19.66%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>Delays in the approval of its RSV vaccines</td>
<td class="has-text-align-center" data-align="center">-8.83%</td>
</tr>
<tr>
<td>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>RSV vaccine delays, along with the dropped COVID-19 vaccine mandate for pregnant women.</td>
<td class="has-text-align-center" data-align="center">-36.05%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: Merck shares were down 0.81% on Wednesday, trading at $79.67, with the stock trading up 0.04% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="147" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-1024x147.png" alt="" class="wp-image-962643" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-1024x147.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM.png 1536w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Merck scores well on Growth in Benzinga&#8217;s Edge Stock Rankings, with a favorable price trend in the short term. How does it compare with Pfizer and Moderna? Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> to find out.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46106134/bernie-sanders-shares-first-thing-he-would-do-as-president-and-it-could-be-a-jab-at-elon-musk" target="_blank" rel="noreferrer noopener">Bernie Sanders Shares First Thing He Would Do As President — And It Could Be A Jab At Elon Musk</a></li>
</ul>
Photo courtesy: lev radin / Shutterstock.com

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

<a href="https://www.youtube.com/watch?v=2PnYYb_xj3U">https://www.youtube.com/watch?v=2PnYYb_xj3U</a>
&nbsp;

Trump Nominee For U.S. CDC Director Monarez Tells Senate Panel She Has Not Seen A Causal Link Between Vaccines And Autism

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Insurance

ABBV

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

Editor's Note: This story has been updated to correct the name of the Citigroup analyst responsible for the downgrade of Merck.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.17%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and increased the price target from $24 to $25 on April 30, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) on June 6 announced in a press release the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) with its partner Pfizer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PFE <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618"><img loading="lazy" decoding="async" width="910" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280.png" alt="" class="wp-image-953567" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053555/image-280-768x711.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.14%</li>
<li>Citigroup analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: The U.S. Food and Drug Administration (FDA) on Friday approved Merck's Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618"><img loading="lazy" decoding="async" width="917" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281.png" alt="" class="wp-image-953569" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053627/image-281-768x691.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.16%</li>
<li>UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $27 to $25 on May 9, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Mizuho analyst Steven Valiquette maintained a Neutral rating and lowered the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On June 5, Dentsply Sirona priced an offering of $550 million of junior subordinated notes.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest XRAY <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0618"><img loading="lazy" decoding="async" width="922" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282.png" alt="" class="wp-image-953570" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18053656/image-282-768x684.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

ARVN

XRAY

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields (CORRECTED)

<a href="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use" title="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use">https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use</a>

'RFK Jr. Weighs Review of Dozens of Shots, Citing Aluminum Use' - Bloomberg News

<a href="https://www.statnews.com/2025/06/18/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary/#:~:text=Prasad%20will%20serve%20as%20the,have%20been%20two%20distinct%20roles" title="https://www.statnews.com/2025/06/18/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary/#:~:text=Prasad%20will%20serve%20as%20the,have%20been%20two%20distinct%20roles">https://www.statnews.com/2025/06/18/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary/#:~:text=Prasad%20will%20serve%20as%20the,have%20been%20two%20distinct%20roles</a>.

'Vinay Prasad Named Chief Medical And Science Officer At FDA' - STAT News

The U.S. Food and Drug Administration (FDA) expanded approval of Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk for disease.
What Happened: The FDA on Thursday approved broader use of Moderna&#8217;s mRESVIA vaccine for younger at-risk adults based on late-stage trial results, reported Reuters.
The mRNA-based shot showed significant immune responses in adults with underlying health conditions and maintained a favorable safety profile. The vaccine was previously limited to adults 60 and older, where it demonstrated 79% efficacy against RSV symptoms.
Health Secretary Robert F. Kennedy Jr. simultaneously <a href="https://www.benzinga.com/news/health-care/25/06/45898417/rfk-jr-appoints-vaccine-critics-to-cdc-vaccine-panel-after-firing-entire-advisory-committee-report">appointed eight new members to the CDC&#8217;s Advisory Committee</a> on Immunization Practices, including prominent mRNA vaccine critics Robert Malone and Retsef Levi.
The health secretary fired all 17 existing panel members, claiming the need to <a href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading">&#8220;re-establish public confidence in vaccine science.&#8221;</a> The committee provides crucial guidance on vaccine recommendations that influence insurance coverage and policy.
The CDC currently recommends RSV vaccines for adults 75 and older, plus those 60-74 at increased risk. The final CDC recommendation remains pending for the expanded age group before availability.
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45919422/trumps-one-big-beautiful-bill-is-the-largest-redistribution-from-poor-to-rich-in-american-history-says-economist-justin-wolfers-amid-tax-cuts-spending-s">Trump&#8217;s &#8216;One Big, Beautiful Bill&#8217; Is &#8216;The Largest Redistribution From Poor To Rich In American History,&#8217; Says Economist Justin Wolfers Amid Tax Cuts, Spending Slashes And Tariffs</a>
Why It Matters: William Blair analysts noted the <a href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals">approval represents</a> &#8220;an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines.&#8221; However, they cautioned that approval alone won&#8217;t massively boost COVID vaccine sales, which depend primarily on overall vaccination market sentiment.
The advisory panel restructuring creates regulatory uncertainty for vaccine manufacturers. Kennedy&#8217;s broader policy changes include removing COVID vaccines from <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">recommended schedules for healthy children and pregnant women</a>, plus terminating Moderna&#8217;s $600 million bird flu vaccine contract.
RSV hospitalizes 15,000-20,000 U.S. adults aged 50-59 annually. Competing vaccines from Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and GSK plc (LSE: GSK) also target similar demographics, intensifying market competition amid shifting federal oversight. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45919626/coinbase-ceo-brian-armstrong-teases-crypto-credit-card-powered-by-american-express-bitcoin-cashbacks-offered-but-heres-the-catch">Coinbase CEO Brian Armstrong Teases Crypto Credit Card Powered By American Express—Bitcoin Cashbacks Offered, But Here&#8217;s The Catch</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Lutsenko_Oleksandr / Shutterstock.com

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC&#8217;s Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after <a href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading">dismissing all 17 existing advisers</a>.
What Happened: The reconstituted panel includes Robert Malone, a prominent mRNA vaccine opponent aligned with Kennedy&#8217;s Make America Healthy Again movement, and Retsef Levi, who has called for the immediate withdrawal of mRNA vaccines, citing serious harm risks, according to a Reuters report.
The committee advises the CDC on immunization schedules after FDA approval, directly influencing insurance coverage and vaccine policy.
Kennedy justified the overhaul to &#8220;re-establish public confidence in vaccine science,&#8221; claiming prior Biden-appointed members had conflicts of interest without providing specific evidence. The new eight-member committee represents the minimum allowed under ACIP&#8217;s founding charter. See Also:<a href="https://www.benzinga.com/markets/equities/25/06/45897549/jim-cramer-says-america-wont-be-truly-liberated-until-it-strikes-rare-earth-deals-with-other-countries-us-doesnt-have-the-cards"> Jim Cramer Says America Won&#8217;t Be &#8216;Truly Liberated&#8217; Until It Strikes Rare-Earth Deals With Other Countries: US Doesn&#8217;t &#8216;Have The Cards&#8217;</a>
Why It Matters: Kennedy previously fired the entire 17-member panel Monday through a Wall Street Journal op-ed, arguing it had become a &#8220;rubber stamp for any vaccine.&#8221;
The Trump administration simultaneously terminated a $600 million Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) contract for mRNA bird flu vaccine development and removed COVID-19 vaccines from recommended schedules for <a href="https://www.benzinga.com/news/health-care/25/06/45810364/rfk-jr-champions-medical-freedom-while-curtailing-access-say-public-health-experts">healthy pregnant women and children</a>. Kennedy&#8217;s broader <a href="https://www.benzinga.com/government/regulations/25/03/44519638/us-department-of-health-and-human-services-aligns-with-trumps-executive-order-to-cut-10k-jobs-save-18-billion">healthcare restructuring eliminated</a> 10,000 HHS positions to save $1.8 billion annually.
Market reaction was mixed, with Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares declining marginally while Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose in after-hours trading. Earlier this year, <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">FDA&#8217;s top vaccine official</a>, Peter Marks, resigned after condemning Kennedy&#8217;s &#8220;misinformation and lies.&#8221;
The new panel will attend the June 25 ACIP meeting, originally scheduled to deliberate flu shots and 2025-26 COVID-19 booster recommendations. Critics argue Kennedy&#8217;s &#8220;medical freedom&#8221; messaging contradicts policies that restrict vaccine access. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45897537/jamie-dimon-recalls-first-palantir-meeting-holy-christ-this-is-unbelievable-jpmorgan-now-has-600-ai-use-cases-2-billion-annual-investment-on-ai">Jamie Dimon Recalls First Palantir Meeting: &#8216;Holy Christ, This Is Unbelievable—&#8217; JPMorgan Now Has 600 AI Use Cases, $2 Billion Annual Investment On AI</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: lev radin / Shutterstock.com

RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report

On Monday, the U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., decided to fire all 17 members of the Advisory Committee on Immunization Practices, a panel that plays a key role in shaping U.S. vaccine policy.
What Happened: In an <a href="https://www.wsj.com/opinion/rfk-jr-hhs-moves-to-restore-public-trust-in-vaccines-45495112">op-ed</a> published in the Wall Street Journal, Kennedy said that this clean sweep was necessary in order to &#8220;re-establish public confidence in vaccine science.&#8221; He argued that the current panel had become a &#8220;rubber stamp for any vaccine&#8221; and was compromised by &#8220;persistent conflicts of interest.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45852346/elon-musk-recently-said-yes-to-impeaching-trump-and-the-odds-of-that-happening-in-2025-rose-on-this-crypto-betting-market">Elon Musk Recently Said &#8216;Yes&#8217; To Impeaching Trump And The Odds Of That Happening In 2025 Rose On This Crypto Betting Market</a>
Kennedy, who has been a vocal anti-vaccine activist even before becoming the country&#8217;s top health official, hasn&#8217;t mentioned who will be appointed to the panel, but has said that the panel would convene within two weeks in Atlanta, according to a <a href="https://apnews.com/article/kennedy-cdc-acip-vaccines-3790c89f45b6314c5c7b686db0e3a8f9">report</a> from the Associated Press.
The ACIP advises the CDC on immunization schedules and insurance coverage guidance, and its recommendations thus carry immense sway on pharma and biotech stocks, especially those with a sizable vaccine portfolio.
Since the announcement was made, most stocks in the sector are in the red in after-hours trade,
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">1 Day</td>
<td class="has-text-align-center" data-align="center">After Hours</td>
<td class="has-text-align-center" data-align="center">Year-To-Date</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td class="has-text-align-center" data-align="center">+2.66%</td>
<td class="has-text-align-center" data-align="center">-0.29%</td>
<td class="has-text-align-center" data-align="center">-9.92%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td class="has-text-align-center" data-align="center">+0.50%</td>
<td class="has-text-align-center" data-align="center">+0.15%</td>
<td class="has-text-align-center" data-align="center">-0.56%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) </td>
<td class="has-text-align-center" data-align="center">+2.48%</td>
<td class="has-text-align-center" data-align="center">-0.85%</td>
<td class="has-text-align-center" data-align="center">-33.00%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)</td>
<td class="has-text-align-center" data-align="center">+0.44%</td>
<td class="has-text-align-center" data-align="center">-0.26%</td>
<td class="has-text-align-center" data-align="center">-5.49%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td class="has-text-align-center" data-align="center">+0.24%</td>
<td class="has-text-align-center" data-align="center">-2.47%</td>
<td class="has-text-align-center" data-align="center">+1.26%</td>
</tr>
</tbody>
</table>
</figure>
Why It Matters: Kennedy has taken several steps against vaccination mandates in recent weeks, starting with the <a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">removal of COVID vaccines</a> from the recommended immunization schedule for healthy pregnant women and children.
Around the same time, the Trump administration <a href="https://www.benzinga.com/government/regulations/25/05/45663794/hhs-cancels-590m-moderna-bird-flu-vaccine-deal-casting-uncertainty-over-pandemic-preparedness-effort">terminated a $600 million contract</a> with Moderna for developing an mRNA-based bird flu vaccine, which was part of former President Joe Biden&#8217;s pandemic preparedness efforts. 
Dr. Matthew Ferrari of the Pennsylvania State University <a href="https://www.benzinga.com/news/health-care/25/06/45810364/rfk-jr-champions-medical-freedom-while-curtailing-access-say-public-health-experts">criticized the health secretary</a>, saying that &#8220;If you restrict access, you necessarily restrict choice,&#8221; referring to the removal of COVID vaccines from the CDC schedule.
Price Action: The iShares U.S. Pharmaceuticals ETF tracks several of the heavyweights across pharma and biotech. On Monday, the fund was up 0.24%, trading at $66.45 per share, but is now down 2.47% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="191" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-1024x191.png" alt="" class="wp-image-944102" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-1024x191.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-300x56.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-768x143.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The ETF is ranked in the 45th percentile according to Benzinga&#8217;s Edge Stock Rankings, and has a favorable price trend in the short term, but not so much in the medium and long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights into the stock, as well as its alternatives. 
Photo Courtesy: Joshua Sukoff on Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45852973/circle-ipo-success-suggests-markets-open-to-new-listings-especially-from-crypto-businesses-says-spac-king-chamath-palihapitiya">Circle IPO Success Suggests Markets Open To New Listings, Especially From Crypto Businesses, Says SPAC King Chamath Palihapitiya</a></li>
</ul>

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading

Press Releases

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Comments

Pfizer

Intérêt court

Pfizer (NYSE:PFE) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL